Past Issue - July 2012 - Vol 15 Issue 3S Index | Previous | Next | 
2012;15;S1-S66. American Society of Interventional Pain Physicians (ASIPP) Guidelines for Responsible Opioid Prescribing in Chronic Non-Cancer Pain: Part I – Evidence Assessment
Laxmaiah Manchikanti, MD, Salahadin Abdi, MD, PhD, Sairam Atluri, MD, Carl C Balog, MD, Ramsin M. Benyamin, MD, Mark V. Boswell, MD, PhD, Keith R Brown, PharmD, Brian M. Bruel, MD, David A. Bryce, MD, Patricia A Burks, LPT, Allen W. Burton, MD, Aaron K. Calodney, MD, David L. Caraway, MD, Kimberly A. Cash, RT, Paul J. Christo, MD, Kim S. Damron, RN, Sukdeb Datta, MD, Timothy R. Deer, MD, Sudhir Diwan, MD, Ike Eriator, MD, Frank J.E. Falco, MD, Bert Fellows, MA, Stephanie Geffert, MLIS, Christopher G. Gharibo, MD, Scott E. Glaser, MD, Jay S. Grider, DO, PhD, Haroon Hameed, MD, Mariam Hameed, MD, Hans Hansen, MD, Michael E. Harned, MD, Salim M. Hayek, MD, PhD, Standiford Helm II, MD, Joshua A. Hirsch, MD, Jeffrey W Janata, PhD, Alan D Kaye, MD, PhD, Adam M Kaye, PharmD, David S. Kloth, MD, Dhanalakshmi Koyyalagunta, MD, Marion Lee, MD, Yogesh Malla, MD, Kavita N. Manchikanti, MD, Carla D. McManus, RN, BSN, Vidyasagar Pampati, MSc, Allan T. Parr, MD, Ramarao Pasupuleti, MD, Vikram B. Patel, MD, Nalini Sehgal, MD, Sanford M. Silverman, MD, Vijay Singh, MD, Howard S. Smith, MD, Lee T Snook, MD, Daneshvari R. Solanki, MD, Deborah H Tracy, MD, Ricardo Vallejo, MD, PhD, and Bradley W. Wargo, DO

BACKGROUND: Opioid abuse has continued to increase at an alarming rate since the 1990s. As documented by different medical specialties, medical boards, advocacy groups, and the Drug Enforcement Administration, available evidence suggests a wide variance in chronic opioid therapy of 90 days or longer in chronic non-cancer pain. Part 1 describes evidence assessment. 

OBJECTIVES: The objectives of opioid guidelines as issued by the American Society of Interventional Pain Physicians (ASIPP) are to provide guidance for the use of opioids for the treatment of chronic non-cancer pain, to produce consistency in the application of an opioid philosophy among the many diverse groups involved, to improve the treatment of chronic non-cancer pain, and to reduce the incidence of abuse and drug diversion. The focus of these guidelines is to curtail the abuse of opioids without jeopardizing non-cancer pain management with opioids.

1) There is good evidence that non-medical use of opioids is extensive; one-third of chronic pain patients may not use prescribed opioids as prescribed or may abuse them, and illicit drug use is significantly higher in these patients.
2) There is good evidence that opioid prescriptions are increasing rapidly, as the majority of prescriptions are from non-pain physicians, many patients are on long-acting opioids, and many patients are provided with combinations of long-acting and short-acting opioids.
3) There is good evidence that the increased supply of opioids, use of high dose opioids, doctor shoppers, and patients with multiple comorbid factors contribute to the majority of the fatalities.
4) There is fair evidence that long-acting opioids and a combination of long-acting and short-acting opioids contribute to increasing fatalities and that even low-doses of 40 mg or 50 mg of daily morphine equivalent doses may be responsible for emergency room admissions with overdoses and deaths.
5) There is good evidence that approximately 60% of fatalities originate from opioids prescribed within the guidelines, with approximately 40% of fatalities occurring in 10% of drug abusers.
6) The short-term effectiveness of opioids is fair, whereas the long-term effectiveness of opioids is limited due to a lack of long-term (> 3 months) high quality studies, with fair evidence with no significant difference between long-acting and short-acting opioids.
7) Among the individual drugs, most opioids have fair evidence for short-term and limited evidence for long-term due to a lack of quality studies.
8) The evidence for the effectiveness and safety of chronic opioid therapy in the elderly for chronic non-cancer pain is fair for short-term and limited for long-term due to lack of high quality studies; limited in children and adolescents and patients with comorbid psychological disorders due to lack of quality studies; and the evidence is poor in pregnant women.
9) There is limited evidence for reliability and accuracy of screening tests for opioid abuse due to lack of high quality studies.
10) There is fair evidence to support the identification of patients who are non-compliant or abusing prescription drugs or illicit drugs through urine drug testing and prescription drug monitoring programs, both of which can reduce prescription drug abuse or doctor shopping.

DISCLAIMER: The guidelines are based on the best available evidence and do not constitute inflexible treatment recommendations. Due to the changing body of evidence, this document is not intended to be a “standard of care.”


Author Information
>> Manuscript Guidelines
>> Rates
>> Ad format requirements

Quick Search in
Pain Physcian
Bradley W. Wargo
Ricardo Vallejo
Deborah H Tracy
Daneshvari R. Solanki
Lee T Snook
Howard S. Smith
Vijay Singh
Sanford M. Silverman
Nalini Sehgal
Vikram B. Patel
Ramarao Pasupuleti
Allan T. Parr
Vidyasagar Pampati
Kavita N. Manchikanti
Carla D. McManus
Yogesh Malla
Marion Lee
Dhanalakshmi Koyyalagunta
David S. Kloth
Adam M Kaye
Alan D Kaye
Jeffrey W Janata
Joshua A. Hirsch
Standiford Helm II
Salim M. Hayek
Michael E. Harned
Hans Hansen
Mariam Hameed
Haroon Hameed
Jay S. Grider
Scott E. Glaser
Christopher G. Gharibo
Stephanie Geffert
Bert Fellows
Frank J.E. Falco
Ike Eriator
Sudhir Diwan
Timothy R. Deer
Sukdeb Datta
Kim S. Damron
Paul J. Christo
Kimberly A. Cash
David L. Caraway
Aaron K. Calodney
Allen W. Burton
Patricia A Burks
David A. Bryce
Brian M. Bruel
Keith R Brown
Mark V. Boswell
Ramsin M. Benyamin
Carl C Balog
Sairam Atluri
Salahadin Abdi
Laxmaiah Manchikanti

Chronic pain
persistent pain
non-cancer pain
controlled substances
substance abuse
prescription drug abuse
prescription monitoring
drug testing
adherence monitoring